Emergent BioSolutions Balance Sheet Health
Financial Health criteria checks 3/6
Emergent BioSolutions has a total shareholder equity of $508.4M and total debt of $662.6M, which brings its debt-to-equity ratio to 130.3%. Its total assets and total liabilities are $1.5B and $969.4M respectively.
Key information
130.3%
Debt to equity ratio
US$662.60m
Debt
| Interest coverage ratio | n/a |
| Cash | US$149.90m |
| Equity | US$508.40m |
| Total liabilities | US$969.40m |
| Total assets | US$1.48b |
Recent financial health updates
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?
Oct 28
Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?
Apr 05Recent updates
Emergent BioSolutions Inc. (NYSE:EBS) Shares Fly 32% But Investors Aren't Buying For Growth
Nov 09Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic
Nov 08Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?
Oct 28Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario
Oct 04Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding
Sep 16Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval
Aug 18Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%
Aug 02Emergent BioSolutions: A Much-Needed Mid-Stage Turnaround In Process
Jul 15Emergent BioSolutions: High-Risk, High-Reward Strategic Turnaround
May 10New CEO Appointment A Clear Positive For Emergent BioSolutions
Feb 27Emergent BioSolutions: Q3 Numbers Leave Work To Be Done
Dec 18Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow
Nov 23Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial
Aug 23Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)
Aug 14Emergent BioSolutions: Making A Big Bet On Narcan
Jul 21An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued
Jun 22Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?
Apr 05Emergent Biosolutions Q4 2022 Earnings Preview
Feb 24An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued
Feb 16Emergent BioSolutions to offload travel health business to Bavarian Nordic for $380M
Feb 15Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments
Dec 07Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance
Nov 09Financial Position Analysis
Short Term Liabilities: EBS's short term assets ($661.4M) exceed its short term liabilities ($229.9M).
Long Term Liabilities: EBS's short term assets ($661.4M) do not cover its long term liabilities ($739.5M).
Debt to Equity History and Analysis
Debt Level: EBS's net debt to equity ratio (100.8%) is considered high.
Reducing Debt: EBS's debt to equity ratio has increased from 80% to 130.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable EBS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: EBS is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 31.1% per year.